JPRN-jRCTs051190013
Completed
Phase 4
Effect of iron containing phosphate binder on iron metabolism of patients undergoing maintenance hemodialysis. - ICBP study
Kuragano Takahiro0 sites64 target enrollmentStarted: May 9, 2019Last updated:
ConditionsChronic kidney disease
Overview
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Kuragano Takahiro
- Enrollment
- 64
Overview
Brief Summary
The results suggested that the avoid aimlessly administration of iron containing phosphate binder could maintain target P, Ca, and PTH levels without iron overload and Hb overshot.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Maintenance hemodialysis patient with high serum phosphate level.
Exclusion Criteria
- •1\) Patients who received maintenance hemodialysis for \< 6month.
- •2\) Patients with severe heart failure (\>NYHA III), respiratory failure, malignancy disease, or severe liver dysfunction.
- •3\) Patient with high serum ferritin level(\>100 ng/mL) at the start of this study.
Investigators
Similar Trials
Unknown
Not Applicable
Effect of iron containing phosphate binder on iron metabolism of patients undergoing maintenance hemodialysis.Chronic kidney diseaseJPRN-UMIN000023700Hyogo College of Medicine300
Completed
Not Applicable
Efficacy of the iron-based phosphate binder in patients on peritoneal dialysis.chronic renal failureJPRN-UMIN000034472Saiseikai Yokohamashi Tobu Hospital100
Completed
Not Applicable
Effect of iron-contained phosphate binder on serum FGF23 in hemodialysis patients.Chronic renal failureJPRN-UMIN000013972Ojiya general hospital30
Completed
Not Applicable
Efficacy and safety of phosphate binders, ferric citrete hydrate and lanthunam carbohydrate, in patients undergoing maintenance hemodialysisJPRN-UMIN000021818Divisions of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine60
Recruiting
Not Applicable
Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler DiseaseRendu Osler DiseaseNCT05544669University Hospital, Strasbourg, France220